Cutaneous Involvement in Waldenström’s Macroglobulinaemia

Cutaneous involvement in Waldenström’s macroglobulinaemia (WM) has been poorly characterized. To describe this involvement, a retrospective study of 19 patients with WM and cutaneous involvement of tumour B cells was performed. Twelve patients (group 1) had lymphoplasmacytic, non-transformed cutaneo...

Full description

Bibliographic Details
Main Authors: Sarah Stien, Eric Durot, Anne Durlach, Marie Beylot-Barry, Henri Adamski, Helmut Beltraminelli, Gérôme Bohelay, Agnès Carlotti, Olivier Carpentier, Pascale Cornillet, Romain Dubois, Nathalie Franck, Bérengère Husson, Liliane Laroche, Eve Maubec, Christian le Clech, Laurent Machet, Nicolas Ortonne, Caroline Ram-Wolff, Béatrice Vergier, Florent Grange
Format: Article
Language:English
Published: Society for Publication of Acta Dermato-Venereologica 2020-08-01
Series:Acta Dermato-Venereologica
Subjects:
Online Access: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3535
Description
Summary:Cutaneous involvement in Waldenström’s macroglobulinaemia (WM) has been poorly characterized. To describe this involvement, a retrospective study of 19 patients with WM and cutaneous involvement of tumour B cells was performed. Twelve patients (group 1) had lymphoplasmacytic, non-transformed cutaneous proliferation, while in 7 cases (group 2) cutaneous involvement corresponded to histological transformation. In group 1, skin involvement was inaugural in 6 cases. The lesions were infiltrated plaques (83%), papules (25%) and tumours (42%). Four patients had a similar clinical picture (purplish, bilateral and symmetrical infiltration on the face). MYD88 L265P mutation was detected in the skin biopsy in all 6 cases tested. The 3-year specific survival rate was 88%. In group 2, cutaneous transformation occurred during the follow-up of the WM (71%). Lesions presented as ulcerated tumours (86%) of the trunk (57%) and lower limbs (57%). The 3-year specific survival rate was 22%. Skin involvement in WM has distinctive characteristics (e.g. clinical, histological, immunohistochemical, MYD88 L265P mutation).
ISSN:0001-5555
1651-2057